Abnormalities in the TGF-β1/SMAD pathways, which are activated by TGF-β and act as transcription factors within the cell, have been detected in relation to Alzheimer’s disease (AD) (Yang and Xu, 2023). This evidence concerns the gene TGFB1 and early-onset autosomal dominant Alzheimer disease.